Comparing the current results to its competitors, Biocardia Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 40.66 %, recorded in the same quarter.
August 29, 2024
In a significant development for cardiology and innovative medical technology, BioCardia, Inc. a burgeoning leader in cellular and cell-derived therapeutics, announced on August 29, 2024, that its Morph DNA Steerable Introducer product family has received market clearance from the U.S. Food and Drug Administration (FDA). This milestone opens up considerable possibilities for enhanced therapeutic interventions, particularly in the realm of cardiovascular and pulmonary diseases, where precise delivery systems are crucial. Key Highlights of the FDA Clearance1. Product Innovation : The Morph DNA Steerable Introducer is designed to provide clinicians with enhanced control and accuracy during cardiac procedures. ...
July 25, 2024
BioCardia, Inc., a prominent figure in cellular therapeutics, has recently announced the commencement of patient enrollment in a pivotal Phase 3 trial assessing its innovative CardiAMP cell therapy. This landmark research, geared toward individuals suffering from ischemic heart failure with reduced ejection fraction (HFrEF), signifies a major stepping stone for both the company and the treatment landscape for cardiovascular diseases. Understanding the Phase 3 TrialThe pivotal trial focuses on the efficacy of CardiAMP, which is derived from a patient’s own cells. This autologous approach aims to stimulate heart tissue repair and regeneration in patients who exhibit a significant decline in heart function. I...
July 8, 2024
In a noteworthy collaboration, CellProthera and BioCardia have achieved success in their Phase II trial of ProtheraCytes for the treatment of Acute Myocardial Infarction (AMI). This breakthrough brings hope for improved therapy options and potentially life-saving advancements for patients suffering from AMI. This article aims to ly outline the key facts surrounding the collaboration and its outcomes, shedding light on its potential implications for the pharmaceutical industry and patient care.1. Background:Acute Myocardial Infarction, commonly known as a heart attack, is a severe and life-threatening condition caused by a lack of blood flow to the heart muscle. It affects millions of people globally, making ...
April 25, 2024
BioCardia Advances Promising Cell Therapy Trials for Cardiovascular Conditions with Encouraging Results and Japanese Approval in SightSUNNYVALE, Calif., Dec. 19, 2023 - BioCardia, Inc. Nasdaq: BCDA, a leading developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, continues to make significant progress in its clinical trials for the treatment of various cardiovascular conditions. The company recently announced the completion of enrollment in its groundbreaking CardiAMP Cell Therapy trial for the treatment of chronic myocardial ischemia, alongside dosing the first patient in its CardiALLO trial for ischemic heart failure. Additionally, BioCardia received positive support...
March 4, 2024
SUNNYVALE, Calif., March 04, 2024 - BioCardia, Inc. (Nasdaq: BCDA), a leading biotechnology company specializing in late-stage cell therapy interventions for cardiovascular disorders, has announced positive interim results from its Phase III randomized controlled trial of CardiAMP autologous cell therapy. The trial involved 110 patients with advanced chronic heart failure at a mean 20-month follow-up period, known as CardiAMP HF.According to the data presented at the Technology and Heart Failure Therapeutics (THT) 2024 annual meeting by Dr. Amish Raval, Director of Clinical Cardiovascular Research and Professor of Medicine at the University of Wisconsin-Madison, the CardiAMP cell therapy demonstrated encou...
Sunnyvale-based company BioCardia, Inc. made a significant leap in the arena of cardiovascular and pulmonary disease therapeutics recently, by administering its maiden dosage in the CardiALLO Allogenic Mesenchymal Cell Therapy Phase I/II trial. The potentially ground-breaking study targets patients afflicted with New York Heart Association Class II and III ischemic heart failure of reduced ejection fraction (HFrEF). In a field that is rapidly expanding, BioCardia has cemented its position as a pioneer by commencing this innovative clinical trial. The initiative s primary objective is to alleviate and manage symptoms associated with ischemic heart failure a condition in which patients hearts can t...
Aura Biosciences Inc is a biotechnology company that focuses on developing and commercializing therapies to treat cancer. They utilize their proprietary Tumor Paint technology to selectively deliver light-activated drugs directly to tumors, aiming to improve treatment outcomes and minimize side effects.
Humacyte Inc is a biotechnology company that focuses on creating bioengineered human tissue constructs for numerous medical applications. Their business model revolves around developing and commercializing their proprietary Humacyl platform, which uses a patient's own cells to create acellular scaffolds that mimic human tissue. These tissue constructs can be used for various purposes such as vascular replacements, functional tissues, and potential regenerative medicine therapies.
Mediwound Ltd operates through the development, manufacturing, and commercialization of biopharmaceutical products. Their business model primarily involves leveraging their expertise in biotechnology to create innovative therapies for the treatment of severe burns, chronic wounds, and other healing disorders.
Mesoblast Ltd is a biotechnology company that operates on a business model focused on the development and commercialization of proprietary cell-based regenerative medicines. They aim to transform the treatment of various degenerative diseases by utilizing their patented technology and strategic partnerships with pharmaceutical companies.
Sources:
Biocardia Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Biocardia Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
